Low Titer Group O Whole Blood for Severe Bleeding in Kids
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
Recruiting
Phase 3
Interventional Study
Hemorrhagic Shock
Trauma Injury
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- Up to 17
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,000 (estimated)
- Sponsor
- Philip Spinella · Other
Who this trial is looking for
This trial is looking for children under 18 who are experiencing life-threatening bleeding from a traumatic injury. Participants will receive either Low Titer Group O Whole Blood or standard treatment to see which is more effective in improving survival.
Are You a Good Fit for This Trial?
You may be able to join if
- I am under 18 years old
- I have a traumatic injury
- I have life-threatening bleeding
- I have low blood pressure for my age
- I have a fast heart rate for my age
- I have signs of severe bleeding, like a deep wound or bruising
You may not be able to join if
- I have a serious brain injury that isn't survivable
- I was activated for massive transfusion but didn't receive any blood
- I needed chest surgery or CPR for more than 5 minutes
- I am pregnant
- I am a prisoner
- I am a ward of the state
- I have only been injured by hanging, drowning, or burns
- I have previously participated in this trial
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion.
The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-c…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
General Inclusion Criteria:
1. Children, defined as less than estimated18 years of age with traumatic injury
2. MTP activation for confirmed or suspected active life-threatening traumatic bleeding
AND
Confirmed or suspected active life-threatening traumatic bleeding with at least 2 of 3 of the fo…
Contacts